



165-1
ifw

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Khan et al.

Serial No.: 10/029,206

Filed: December 21, 2001

For: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Confirmation No.: 5353

Examiner: To be assigned

Group Art Unit: 1651

Attorney Docket No.: 2183-5222US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 11, 2004
Date

Betty Vowles
Signature

Betty Vowles
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#US - 5,380,668	01-10-1995	Herron
#US - 2003/0186244 A1	10-02-2003	Margus et al.
#US - 2003/0113733 A1	06-19-2003	Khan et al.
#US - 2003/0119720 A1	06-26-2003	Khan et al.
#US - 2002/0064501 A1	05-30-2002	Khan et al.
#US - 2003/0166556 A1	09-04-2003	Khan et al.
#US - 2003/0215434 A1	11-20-2003	Khan et al.
#US - 2003/0219425 A1	11-27-2003	Khan et al.
#US - 2003/0220257 A1	11-27-2003	Benner et al.
#US - 2003/0220258 A1	11-27-2003	Benner et al.
#US - 2003/0220259 A1	11-27-2003	Benner et al.
#US - 2003/0220260 A1	11-27-2003	Khan et al.
#US - 2003/0220261 A1	11-27-2003	Khan et al.
#US - 2003/0224995 A1	12-04-2003	Khan et al.
#US - 2004/0013661 A1	01-22-2004	Wensvoort et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#WO 03/029292 A2	04-10-2003	Erasmus Universiteit Rotterdam

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/821,380

Filed: March 29, 2001

For: IMMUNOREGULATOR, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):



Serial No.: 10/029,206

Attorney Docket No.: 3077-6084US
Serial No.: 10/753,510
Filing Date: 1/7/2004
Title: IMMUNOREGULATORY COMPOSITIONS

Attorney Docket No.: 3077-6420US
Serial No.: 10/821,256
Filing Date: 4/8/2004
Title: COMPOSITIONS CAPABLE OF REDUCING ELEVATED BLOOD UREA CONCENTRATION

Attorney Docket No.: 3077-6384US
Serial No.: 10/821,240
Filing Date: 4/8/2004
Title: METHODS AND USES FOR PROTEIN BREAKDOWN PRODUCTS

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Allen C. Turner".

Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: May 7, 2004
ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08
Cited Documents

Document in ProLaw



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 1

Complete if Known

Application Number	10/029,206
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1651
Examiner Name	To be assigned
Attorney Docket Number	2183-5222US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		#US-5,380,668	01-10-1995	Herron	
		#US- 2003/0186244 A1	10-02-2003	Margus et al.	
		#US- 2003/0113733 A1	06-19-2003	Khan et al.	
		#US- 2003/0119720 A1	06-26-2003	Khan et al.	
		#US- 2002/0064501 A1	05-30-2002	Khan et al.	
		#US- 2003/0166556 A1	09-04-2003	Khan et al.	
		#US- 2003/0215434 A1	11-20-2003	Khan et al.	
		#US- 2003/0219425 A1	11-27-2003	Khan et al.	
		#US- 2003/0220257 A1	11-27-2003	Benner et al.	
		#US- 2003/0220258 A1	11-27-2003	Benner et al.	
		#US- 2003/0220259 A1	11-27-2003	Benner et al.	
		#US- 2003/0220260 A1	11-27-2003	Khan et al.	
		#US- 2003/0220261 A1	11-27-2003	Khan et al.	
		#US- 2003/0224995 A1	12-04-2003	Khan et al.	
		#US- 2004/0013661 A1	01-22-2004	Wensvoort et al.	
	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		#WO 03/029292 A2	04-10-2003	Erasmus Universiteit Rotterdam		

Examiner Signature	Date Considered
--------------------	-----------------

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/821,380

Filed: March 29, 2001

For: IMMUNOREGULATOR, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.